154 related articles for article (PubMed ID: 20439632)
1. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Ivy P; Chen HX; Dowlati A; Dreicer R
J Clin Oncol; 2010 Jun; 28(17):e284-5; author reply e286-7. PubMed ID: 20439632
[No Abstract] [Full Text] [Related]
2. From theoretical synergy to clinical supra-additive toxicity.
Soria JC; Massard C; Izzedine H
J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
[No Abstract] [Full Text] [Related]
3. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
Medioni J; Banu E; Helley D; Scotte F; Fournier L; Mejean A; Chedid A; Azizi M; Andrieu JM; Oudard S
Eur Urol; 2009 Jul; 56(1):207-11; quiz 211. PubMed ID: 19157688
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of first-line therapy for metastatic renal cell carcinoma.
Porta C; Szczylik C
Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
[TBL] [Abstract][Full Text] [Related]
6. Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
Charbonneau C; Sandin R
Br J Cancer; 2010 Oct; 103(8):1307-8; author reply 1309-10. PubMed ID: 20938457
[No Abstract] [Full Text] [Related]
7. Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
Porta C
Br J Cancer; 2010 Mar; 102(7):1196-7. PubMed ID: 20179707
[No Abstract] [Full Text] [Related]
8. [First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO].
Rexer H; Doehn C
Urologe A; 2016 Sep; 55(9):1242-3. PubMed ID: 27422311
[No Abstract] [Full Text] [Related]
9. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Schmidinger M; Zielinski CC
Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Hutson TE; Figlin RA; Kuhn JG; Motzer RJ
Oncologist; 2008 Oct; 13(10):1084-96. PubMed ID: 18838439
[TBL] [Abstract][Full Text] [Related]
11. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G
Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs.
Prescrire Int; 2009 Aug; 18(102):165. PubMed ID: 19746526
[No Abstract] [Full Text] [Related]
13. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
Thompson Coon JS; Liu Z; Hoyle M; Rogers G; Green C; Moxham T; Welch K; Stein K
Br J Cancer; 2009 Jul; 101(2):238-43. PubMed ID: 19568242
[TBL] [Abstract][Full Text] [Related]
15. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.
Bruce JY; Kolesar JM; Hammers H; Stein MN; Carmichael L; Eickhoff J; Johnston SA; Binger KA; Heideman JL; Perlman SB; Jeraj R; Liu G
Cancer Chemother Pharmacol; 2014 Mar; 73(3):485-93. PubMed ID: 24414551
[TBL] [Abstract][Full Text] [Related]
16. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
Ravasio R; Ortega C; Sabbatini R; Porta C
Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
19. Exploring the role of novel agents in the treatment of renal cell carcinoma.
Maluf FC; Fernandes Gdos S; Kann AG; Aguilar-Ponce JL; de la Garza J; Buzaid AC
Cancer Treat Rev; 2008 Dec; 34(8):750-60. PubMed ID: 18801619
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
